about
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsIn vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian CancerCholine Metabolism Alteration: A Focus on Ovarian CancerKey nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancerAugmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancersEffect of Pantethine on Ovarian Tumor Progression and Choline Metabolism.Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.Epigenetic control of autophagy by microRNAs in ovarian cancerActivation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines.Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancerT-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.A step further in understanding the biology of the folate receptor in ovarian carcinoma.Targeting of anti-tumor responses with bispecific antibodies.MiR-506: A Multitasker in Suppression of the Epithelial-to-Mesenchymal TransitionAnti-CD3/anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model.Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinomaIL-27 induces the expression of IDO and PD-L1 in human cancer cells.Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer.Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.miRNA control of apoptotic programs: focus on ovarian cancer.Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.M-CAM expression as marker of poor prognosis in epithelial ovarian cancer.Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
P50
Q26738643-46029CB7-0E7D-4035-8CD4-CABB9731B406Q26742109-A5BA2198-1287-4B76-AA62-E849E53747F4Q26742116-4194AA30-B44C-42CD-9616-78407364113DQ28082679-64BCD415-F6B5-4224-9E9F-D160A742FC1DQ28262260-A6459F35-A0AB-4BDD-B12E-8F285688F42CQ31145516-C4BB9022-65D8-42DC-95FF-4FD1E276A1B8Q32097568-4CF4BDE5-833B-476B-AFDC-144F091CD165Q33615837-F72F7BA5-7513-4E00-B743-D3D420041BF3Q33699139-97049271-251A-4E11-A1C9-9651908F69EFQ34217159-3E0C532D-21D1-42A9-8FD4-4852D410F2B7Q34618963-084E8495-427F-4447-AF58-16CF9B8C7675Q34718013-F985BD78-183E-4258-A158-8A173F4C1A3DQ35027806-0FCA8E70-3A7D-4E5D-94C7-B6BA67E1D814Q35066040-63F58C46-DB71-40F7-96CC-8CE5E36E23FCQ35548537-A5AFB42C-DE91-4726-B596-02C4FF3578A9Q35660799-41B30D5C-9E6E-4936-8CF2-2F64979EA28FQ35750258-DEF9F777-A11C-494A-AF01-940F5824EB80Q35793767-10EDE758-D605-4D14-BA84-8FB58D340287Q36685395-697BB57C-F680-4877-9033-A60137DC7825Q36870100-0EDEA04E-9257-4131-82D1-1B3C132C4559Q37507405-205C4C5B-1593-4738-B596-2D3B6967FFC0Q37559012-6170288F-3C11-4C2F-9A15-36BABF8726C4Q37637257-76A08921-24E1-4E7D-B7E1-B3E6EE495AB6Q37662851-4BFFDEFC-1B5B-4200-8CB0-4CF6A06523D0Q37687273-B508AD49-85DA-499F-9B77-8C0284968DD2Q37706857-7E32DAA3-27D1-49B2-A91E-967FB17E23F1Q37861225-EE3C8B36-EEFD-4BD9-9759-05EBEF1EAA29Q38096411-2B630879-BFAF-44EA-BCB0-2CD010BFE34AQ38262333-80F1C901-6FF5-4CF1-9081-0B940DDF550EQ38262336-FF78D4C3-FBEB-4AE8-9C61-B30AAEC99D90Q38262338-51B86FCC-C92B-496F-B989-193EC3E0A06DQ38832657-3EAF049E-A242-4D53-8EED-7E71B3E20825Q39122547-3B6BA47D-6579-49A0-AAC2-95ECE2289572Q39241466-44D9E08C-4E88-4D82-88D3-0624BD07B1A3Q39454124-C8F30A5C-16DA-40F1-9CBD-A8B51166A24FQ40028830-9D8050DB-0506-4AE2-90C2-B64F0CAF001FQ40076587-6247BC7D-1E46-4D2F-986C-CC7D860C2282Q40169753-FB65CBC7-C08E-4540-B00C-7AFB733F047CQ40262325-F7E48ED6-94A1-40CC-B5A1-6088F523EB7BQ40296292-AD2130E5-FF76-4EB0-82B2-566312C36698
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Delia Mezzanzanica
@ast
Delia Mezzanzanica
@en
Delia Mezzanzanica
@es
Delia Mezzanzanica
@nl
Delia Mezzanzanica
@sl
type
label
Delia Mezzanzanica
@ast
Delia Mezzanzanica
@en
Delia Mezzanzanica
@es
Delia Mezzanzanica
@nl
Delia Mezzanzanica
@sl
altLabel
Mezzanzanica D.
@en
prefLabel
Delia Mezzanzanica
@ast
Delia Mezzanzanica
@en
Delia Mezzanzanica
@es
Delia Mezzanzanica
@nl
Delia Mezzanzanica
@sl
P1053
C-2607-2017
P106
P1153
7003807736
P21
P2798
P31
P3829
P496
0000-0002-9664-6871